Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Cancer Sci. 2014 Apr;105(4):437-44. doi: 10.1111/cas.12361. Epub 2014 Mar 8.
BACH2, a B cell-specific transcriptional repressor, plays a significant role in B cell maturation. Despite a number of previous studies, the clinicopathological significance of BACH2 expression in diffuse large B cell lymphoma (DLBCL) remains to be established. The present study was performed to validate the significance of BACH2 expression as a predictor of prognosis in DLBCL. A total of 94 DLBCL cases were included in the present study. All were diagnosed between 2008 and 2011, and thorough clinical and pathological investigations were possible, including immunohistochemical analysis of BACH2. Eighteen cases were selected by positive MYC gene alteration (MYC+ group) according to cytogenetic study. The remaining 76 cases were subclassified into germinal center B cell phenotype (GCB group, 38 cases) or non-GCB phenotype (non-GCB group, 38 cases). There were no significant differences between the two groups with regard to clinical characteristics and outcomes. In the GCB group, 21 cases were judged to have high BACH2 expression, with 19 cases in the non-GCB group. In cases with high BACH2 expression in GCB and non-GCB groups, the 3-year overall survival (OS) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256). In the MYC+ group, 15 cases had high BACH2 expression levels. Although overall the MYC+ group showed short survival time (3-year OS 35.0%), 3 out of 4 cases with low BACH2 expression are alive without disease relapse at the time of publication of this paper. In conclusion, BACH2 expression level is a promising predictor of prognosis for DLBCL.
BACH2 是一种 B 细胞特异性转录抑制剂，在 B 细胞成熟过程中发挥重要作用。尽管已有多项研究，但 BACH2 表达在弥漫性大 B 细胞淋巴瘤（DLBCL）中的临床病理意义仍有待确定。本研究旨在验证 BACH2 表达作为 DLBCL 预后预测因子的意义。本研究共纳入 94 例 DLBCL 病例。所有病例均于 2008 年至 2011 年间诊断，且可进行全面的临床和病理研究，包括 BACH2 的免疫组织化学分析。根据细胞遗传学研究，18 例病例被选择为 MYC 基因改变阳性（MYC+组）。其余 76 例病例分为生发中心 B 细胞表型（GCB 组，38 例）或非生发中心 B 细胞表型（非 GCB 组，38 例）。两组的临床特征和结局无显著差异。在 GCB 组中，有 21 例判断为高 BACH2 表达，非 GCB 组有 19 例。在 GCB 和非 GCB 组中高 BACH2 表达的病例中，3 年总生存率（OS）显著短于低表达病例（71.7%比 91.3%，P=0.0256）。在 MYC+组中，有 15 例高 BACH2 表达水平。尽管总体而言，MYC+组的生存时间较短（3 年 OS 为 35.0%），但在本文发表时，4 例低 BACH2 表达的病例中有 3 例无疾病复发且存活。总之，BACH2 表达水平是预测 DLBCL 预后的有前途的指标。
